



## Personalis to Announce Third Quarter Financial Results on November 4, 2021

October 21, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 21, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021. In conjunction with the release, the company will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 7896264. The live webinar of the call may be accessed by visiting the Events section of the company's website at [investors.personalis.com](https://investors.personalis.com). A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

### About Personalis, Inc.

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform](#)® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis [Clinical Laboratory](#) is built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit [www.personalis.com](https://www.personalis.com) and follow Personalis on Twitter ([@PersonalisInc](#)).

### Forward-Looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, the company's business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis' filings with the U.S. Securities and Exchange Commission, including the company's most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Personalis disclaims any obligation to update such forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211021005038/en/): <https://www.businesswire.com/news/home/20211021005038/en/>

### Investor Relations Contact:

Caroline Corner  
[investors@personalis.com](mailto:investors@personalis.com)  
415-202-5678

### Media Contact:

Jennifer Havlek  
[pr@personalis.com](mailto:pr@personalis.com)  
[www.personalis.com](https://www.personalis.com)  
650-752-1300

Source: Personalis, Inc.